Compare Lupin Ltd with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs CADILA HEALTHCARE - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN CADILA HEALTHCARE LUPIN/
CADILA HEALTHCARE
 
P/E (TTM) x -129.2 29.9 - View Chart
P/BV x 2.9 3.6 80.7% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 LUPIN   CADILA HEALTHCARE
EQUITY SHARE DATA
    LUPIN
Mar-19
CADILA HEALTHCARE
Mar-19
LUPIN/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs986432 228.0%   
Low Rs720306 235.1%   
Sales per share (Unadj.) Rs369.5128.6 287.3%  
Earnings per share (Unadj.) Rs13.418.5 72.3%  
Cash flow per share (Unadj.) Rs37.424.4 153.2%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs303.7101.5 299.3%  
Shares outstanding (eoy) m452.491,023.74 44.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.32.9 80.4%   
Avg P/E ratio x63.619.9 319.6%  
P/CF ratio (eoy) x22.815.1 150.7%  
Price / Book Value ratio x2.83.6 77.2%  
Dividend payout %018.9 0.0%   
Avg Mkt Cap Rs m386,064378,170 102.1%   
No. of employees `00017.712.4 142.2%   
Total wages/salary Rs m31,51321,241 148.4%   
Avg. sales/employee Rs Th9,453.810,585.0 89.3%   
Avg. wages/employee Rs Th1,782.01,707.8 104.3%   
Avg. net profit/employee Rs Th343.01,526.5 22.5%   
INCOME DATA
Net Sales Rs m167,182131,656 127.0%  
Other income Rs m3,6402,011 181.0%   
Total revenues Rs m170,822133,667 127.8%   
Gross profit Rs m28,82229,731 96.9%  
Depreciation Rs m10,8505,986 181.3%   
Interest Rs m3,0781,935 159.1%   
Profit before tax Rs m18,53423,821 77.8%   
Minority Interest Rs m-89469 -19.0%   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,0175,303 170.0%   
Profit after tax Rs m6,06618,987 31.9%  
Gross profit margin %17.222.6 76.3%  
Effective tax rate %48.722.3 218.5%   
Net profit margin %3.614.4 25.2%  
BALANCE SHEET DATA
Current assets Rs m138,53684,981 163.0%   
Current liabilities Rs m61,29973,425 83.5%   
Net working cap to sales %46.28.8 526.3%  
Current ratio x2.31.2 195.3%  
Inventory Days Days8475 112.4%  
Debtors Days Days112110 102.6%  
Net fixed assets Rs m127,516133,493 95.5%   
Share capital Rs m9051,024 88.4%   
"Free" reserves Rs m136,517102,839 132.7%   
Net worth Rs m137,422103,863 132.3%   
Long term debt Rs m66,41739,497 168.2%   
Total assets Rs m279,494234,831 119.0%  
Interest coverage x7.013.3 52.7%   
Debt to equity ratio x0.50.4 127.1%  
Sales to assets ratio x0.60.6 106.7%   
Return on assets %3.38.9 36.7%  
Return on equity %4.418.3 24.1%  
Return on capital %8.918.3 48.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41448,404 122.7%   
Fx outflow Rs m22,28211,593 192.2%   
Net fx Rs m37,13236,811 100.9%   
CASH FLOW
From Operations Rs m16,66028,823 57.8%  
From Investments Rs m-32,825-57,387 57.2%  
From Financial Activity Rs m7,44118,846 39.5%  
Net Cashflow Rs m-8,724-7,105 122.8%  

Share Holding

Indian Promoters % 46.6 74.8 62.3%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 8.3 136.1%  
FIIs % 31.9 5.9 540.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 11.0 91.8%  
Shareholders   98,259 44,069 223.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   NATCO PHARMA  ELDER PHARMA  SUVEN LIFESCIENCES  PANACEA BIOTECH  WOCKHARDT  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 466 Points Higher; Energy, Auto and Realty Stocks Rally(Closing)

Indian share markets extended gains as the session progressed and ended on a strong note, driven by automobile stocks and index heavyweight Reliance Industries.

Related Views on News

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Jul 6, 2020 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS